- Home
- JMIA vs ATYR Comparison
JMIA vs ATYR Comparison
Compare JMIA & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JMIA
- ATYR
- Stock Information
- Founded
- JMIA 2012
- ATYR 2005
- Country
- JMIA Germany
- ATYR United States
- Employees
- JMIA N/A
- ATYR N/A
- Industry
- JMIA Catalog/Specialty Distribution
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JMIA Consumer Discretionary
- ATYR Health Care
- Exchange
- JMIA Nasdaq
- ATYR Nasdaq
- Market Cap
- JMIA 297.6M
- ATYR 306.2M
- IPO Year
- JMIA 2019
- ATYR 2015
- Fundamental
- Price
- JMIA $3.24
- ATYR $5.39
- Analyst Decision
- JMIA Buy
- ATYR Strong Buy
- Analyst Count
- JMIA 2
- ATYR 6
- Target Price
- JMIA $7.88
- ATYR $18.60
- AVG Volume (30 Days)
- JMIA 3.4M
- ATYR 1.8M
- Earning Date
- JMIA 05-08-2025
- ATYR 05-07-2025
- Dividend Yield
- JMIA N/A
- ATYR N/A
- EPS Growth
- JMIA N/A
- ATYR N/A
- EPS
- JMIA N/A
- ATYR N/A
- Revenue
- JMIA $154,854,000.00
- ATYR N/A
- Revenue This Year
- JMIA $12.94
- ATYR $1,264.26
- Revenue Next Year
- JMIA $3.94
- ATYR $1,239.11
- P/E Ratio
- JMIA N/A
- ATYR N/A
- Revenue Growth
- JMIA N/A
- ATYR N/A
- 52 Week Low
- JMIA $1.60
- ATYR $1.42
- 52 Week High
- JMIA $15.04
- ATYR $5.75
- Technical
- Relative Strength Index (RSI)
- JMIA 56.94
- ATYR 82.89
- Support Level
- JMIA $3.10
- ATYR $4.16
- Resistance Level
- JMIA $3.38
- ATYR $3.94
- Average True Range (ATR)
- JMIA 0.22
- ATYR 0.36
- MACD
- JMIA -0.02
- ATYR 0.18
- Stochastic Oscillator
- JMIA 55.12
- ATYR 87.00
About JMIA Jumia Technologies AG each representing two
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates majority of its revenue from the West Africa segment.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.